Anavex Life Sciences Corp. (AVXL) News
Filter AVXL News Items
AVXL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AVXL News Highlights
- For AVXL, its 30 day story count is now at 6.
- Over the past 10 days, the trend for AVXL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AVXL are DEC, EU and GENE.
Latest AVXL News From Around the Web
Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAAThe CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise. |
Anavex Life Sciences Stock Sees RS Rating Jump To 86; Is It One To Watch?Anavex Life Sciences now clears that threshold, with a jump from 66 to 86 Wednesday. IBD's unique rating identifies price performance with a 1 (worst) to 99 (best) score. Over 100 years of market history shows that the market's biggest winners often have an RS Rating of above 80 as they begin their biggest price moves. |
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett SyndromeSignificant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX®2-73 in Rett syndrome patients Heatmap Heatmap NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndro |
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s DiseaseNEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of an application for a Uni |
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 401.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call TranscriptAnavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript November 27, 2023 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.16. Operator: Good morning, and welcome to the Anavex Life Sciences Fiscal 2023 Fourth Quarter Conference Call. My name is Clint Tomlinson and I will be your host for […] |
Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 468.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Wall Street Slumps As "Fear Gauge" Mounts ComebackWall Street is placing its four-week rally on hold, as investors watch the retail sector following an online record-setting Black Friday and await this week's slew of economic data. |
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business UpdateCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended |